77 Per Cent of Multiple Myeloma Patients Showed Reduction or Stabilization in Myeloma -M- Protein Levels in Preliminary Phase II Data for Proteasome Inhibitor Bortezomib

In this article Millennium Pharmaceuticals, Inc. updated the preliminary findings of a phase II clinical trial of its investigational drug bortezomib in patients with multiple myeloma, the second most common haematologic cancer, whose disease has relapsed and not responded following multiple prior treatments. The study results showed that bortezomib (formerly known as MLN341, LDP-341 and PS-341) stabilized or reduced myeloma (M) protein (a primary marker of cancer burden) in 77 per cent of patients in the trial evaluated at this time.

Provided by: Millennium Pharmaceuticals Topic: Software Date Added: Oct 2002 Format: HTML

Find By Topic